August 30, 2018 – By Estela Ashley
P-A-W Capital Corp decreased its stake in Chemocentryx Inc (CCXI) by 53.13% based on its latest 2018Q1 regulatory filing with the SEC. P-A-W Capital Corp sold 85,000 shares as the company’s stock rose 32.26% while stock markets declined. The hedge fund held 75,000 shares of the health care company at the end of 2018Q1, valued at $1.02 million, down from 160,000 at the end of the previous reported quarter. P-A-W Capital Corp who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $645.85M market cap company. The stock increased 0.47% or $0.06 during the last trading session, reaching $12.82. About 12,425 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 83.50% since August 30, 2017 and is uptrending. It has outperformed by 70.93% the S&P500. Some Historical CCXI News: 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA
Crosslink Capital Inc decreased its stake in Zendesk Inc (ZEN) by 72.06% based on its latest 2018Q1 regulatory filing with the SEC. Crosslink Capital Inc sold 573,742 shares as the company’s stock rose 30.39% while stock markets declined. The hedge fund held 222,456 shares of the technology company at the end of 2018Q1, valued at $10.65 million, down from 796,198 at the end of the previous reported quarter. Crosslink Capital Inc who had been investing in Zendesk Inc for a number of months, seems to be less bullish one the $7.34B market cap company. The stock increased 0.09% or $0.06 during the last trading session, reaching $69.29. About 118,457 shares traded. Zendesk, Inc. (NYSE:ZEN) has risen 119.18% since August 30, 2017 and is uptrending. It has outperformed by 106.61% the S&P500. Some Historical ZEN News: 08/03/2018 ZENDESK INC ZEN.N : UBS RAISES TARGET PRICE TO $46 FROM $43; 21/05/2018 – ZENDESK INC ZEN.N : BOFA MERRILL RAISES PRICE OBJECTIVE TO $64 FROM $60; 01/05/2018 – Zendesk Sees 2018 Rev $565M-$572M; 10/05/2018 – Zendesk to Hold Annual Analyst & Investor Day on May 17, 2018; 22/03/2018 – Research Links Employee Volunteering With Happier Customers; 03/04/2018 – ZENDESK SAYS IT SURPASSES $500M ANNUAL REV. RUN RATE; 03/04/2018 – Zendesk Surpasses $500M Annual Revenue Run Rate; Continues Enterprise Expansion With New Al-Powered Enterprise Self-Service Product; 18/05/2018 – ZENDESK INC ZEN.N : CRAIG-HALLUM RAISES TARGET PRICE TO $63; 19/04/2018 – DJ Zendesk Inc, Inst Holders, 1Q 2018 (ZEN); 03/04/2018 – Zendesk: Surpasses $500M Annual Rev Run Rate
Investors sentiment decreased to 1 in Q1 2018. Its down 0.30, from 1.3 in 2017Q4. It dived, as 10 investors sold CCXI shares while 36 reduced holdings. 24 funds opened positions while 22 raised stakes. 24.22 million shares or 3.03% more from 23.51 million shares in 2017Q4 were reported. American Gru Inc stated it has 15,795 shares. 37,100 are held by New York State Common Retirement Fund. Jane Street Grp Inc Limited Company has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Vanguard Group Inc holds 1.22M shares. Carmignac Gestion owns 390,097 shares. Schwab Charles Management invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Spark Mgmt Limited Liability Corp holds 0.05% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 62,600 shares. Franklin Resource holds 0.01% or 1.69 million shares in its portfolio. Banque Pictet Cie Sa reported 54,178 shares. Panagora Asset owns 369,959 shares. Acadian Asset Mgmt Ltd Co invested in 0.03% or 521,864 shares. Wells Fargo & Commerce Mn reported 0% stake. 19,000 are held by State Of Wisconsin Invest Board. California State Teachers Retirement Systems holds 38,188 shares. 625 were reported by Thompson Davis And Com.
P-A-W Capital Corp, which manages about $83.23M US Long portfolio, upped its stake in Allot Communications Ltd (NASDAQ:ALLT) by 120,000 shares to 700,000 shares, valued at $3.77M in 2018Q1, according to the filing. It also increased its holding in Quotient Technology Inc by 70,000 shares in the quarter, for a total of 230,000 shares, and has risen its stake in Eiger Biopharmaceuticals Inc.
Among 7 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. ChemoCentryx had 10 analyst reports since September 3, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 8 by Cowen & Co. The rating was maintained by JP Morgan with “Overweight” on Tuesday, March 13. The firm has “Neutral” rating by JP Morgan given on Tuesday, August 14. The stock has “Sell” rating by Zacks on Monday, September 21. On Thursday, August 10 the stock rating was maintained by JMP Securities with “Buy”. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Mkt Outperform” rating given on Tuesday, February 21 by JMP Securities. As per Thursday, September 3, the company rating was downgraded by Zacks.
Analysts await ChemoCentryx, Inc. (NASDAQ:CCXI) to report earnings on November, 6. They expect $-0.25 earnings per share, down 92.31% or $0.12 from last year’s $-0.13 per share. After $-0.14 actual earnings per share reported by ChemoCentryx, Inc. for the previous quarter, Wall Street now forecasts 78.57% negative EPS growth.
Since May 1, 2018, it had 0 insider buys, and 12 selling transactions for $7.89 million activity. Cappel Markus J. had sold 50,000 shares worth $590,637. 200,000 shares were sold by Schall Thomas J., worth $2.36 million on Tuesday, May 15.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals …” on August 20, 2018, also Nasdaq.com with their article: “ChemoCentryx to Present at Two Upcoming Investor Conferences” published on August 22, 2018, Seekingalpha.com published: “ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q2 2018 Results – Earnings Call Transcript” on August 10, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx 2018 Q2 – Results – Earnings Call Slides” published on August 10, 2018 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Reports Second Quarter 2018 Financial Results and Recent Highlights” with publication date: August 09, 2018.
Analysts await Zendesk, Inc. (NYSE:ZEN) to report earnings on November, 7. They expect $-0.24 EPS, up 7.69% or $0.02 from last year’s $-0.26 per share. After $-0.25 actual EPS reported by Zendesk, Inc. for the previous quarter, Wall Street now forecasts -4.00% EPS growth.
Another recent and important Zendesk, Inc. (NYSE:ZEN) news was published by Seekingalpha.com which published an article titled: “Zendesk: The Streak Won’t Last Forever” on August 01, 2018.
Crosslink Capital Inc, which manages about $2.09B and $498.50 million US Long portfolio, upped its stake in Paypal Holdings by 96,070 shares to 233,410 shares, valued at $17.71 million in 2018Q1, according to the filing. It also increased its holding in Class A by 288,765 shares in the quarter, for a total of 1.59M shares, and has risen its stake in Worldpay Inc (NYSE:VNTV).
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.